ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1623842
MMP14 as a Central Mediator of TGF-β1-Induced Extracellular Matrix Remodeling in Graves' orbitopathy
Provisionally accepted
- Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Graves' orbitopathy (GO) is an autoimmune orbital disorder characterized by chronic inflammation and aberrant extracellular matrix (ECM) remodeling, leading to progressive fibrosis. Recent studies implicate matrix metalloproteinase‑14 (MMP14) in ECM degradation and tissue remodeling, yet its precise role in GO remains unclear. Design and methods Orbital adipose/connective tissues specimens were obtained from GO patients (stratified into type I and type II based on clinical classification) and non‑GO controls. High‑throughput RNA sequencing identified differentially expressed genes, focusing on MMP‑related transcripts. MMP14 expression was quantified by immunohistochemistry and Western blotting, correlating its levels with fibrotic grade. Primary orbital fibroblasts (OFs) isolated from GO and control subjects were cultured and stimulated with TGF‑β1. Quantitative real‑time PCR and Western blot assays evaluated MMP14 and fibroblast activation markers (α‑SMA, COL1A1, CTGF). Transcriptomic profiling of TGF‑β1–treated OFs and a scratch wound assay further assessed the effect of the MMP14 inhibitor NSC‑405020 on cellular motility.Results GO type II tissues demonstrated a significant upregulation of MMP14, which correlated positively with fibrosis severity. GO‑ derived OFs exhibited higher basal and TGF‑β1–induced MMP14 and fibrotic marker expression compared to controls. Transcriptomic analysis revealed activation of ECM–receptor interaction, PI3K‑Akt, and MAPK signaling pathways enriched for MMP‑associated genes. Pharmacologic inhibition of MMP14 attenuated TGF‑β1–induced fibrotic markers and reduced OFs migration.Conclusion These findings indicate that MMP14 is a central mediator in GO fibrotic remodeling, highlighting its potential as a therapeutic target to alleviate orbital fibrosis. Further mechanistic studies are needed to clarify MMP14’s role in GO progression.
Keywords: Graves' Orbitopathy (GO), matrix metalloproteinase 14 (MMP14), Fibrosis, Extracellular Matrix, Tissue remodeling
Received: 06 May 2025; Accepted: 27 Jun 2025.
Copyright: © 2025 Wang, Lu, He, Shu, Lin, Su and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Peng Wang, Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.